t-cell engager bispecific formats of an aml patient ... · 3. at1413 t-cellengagersinducet...
TRANSCRIPT
10-10 10-9 10-8
0
20
40
60
80
concentration [M]
cyto
toxi
city
[%]
136.2
EC50: 620 pM
10-10 10-9 10-8
0
20
40
60
80
concentration [M]
cyto
toxi
city
[%]
A375
EC50: 550 pM
Isotype control bTCE
AT1413 bTCE
AT1002 bTCEAT1413 bTCEAT1002 KiHAT1413 KiH
10-11 10-10 10-9 10-8 10-7-20
0
20
40
60
80
concentration [M]
cyto
toxi
city
[%]
EC50: 27 nM
EC50: 500 pM
Isotype control bTCE
AT1413 bTCE
Isotype control KiH
AT1413 KiH
AT1002 bTCEAT1413 bTCEAT1002 KiHAT1413 KiH
AT1002 bTCEAT1413 bTCEAT1002 KiHAT1413 KiH
0 7 14 21 28 350
50
100
150
200
250
Days since tumor engraftment
Nor
mal
ized
tum
or g
row
th
0
50
100
150
200
250
Norm
aliz
ed tu
mor
gro
wth Isotype control
bTCE2.5 mg/kg
AT1413 bTCE2.5 mg/kg
Isotype controlKiH1.5 mg/kg
0 7 14 21 28 35Days since tumor engraftment
AT1413KiH1.5 mg/kg
0 357 14 21 28
biweekly I.V. antibody injection
sacrifice
A375, S.C.2x106 cells
caliper measurement of tumor size
Nor
mal
ized
tum
or g
row
thDays since tumor engraftment
anti-humanIgG-AF647
A375melanoma
Isotype controlAT1413
Untreated
Neuraminidase
136.2melanoma
THP-1AML
Isotyp
e ctr
AT14
13
MXinput
A37
5
IP
150kDa
100kDa75kDa
I
III
II
IV
50μm
50μm
50μm
50μm
50μm
50μm
100μm
100μm
Isotype control
AT1413 AT1413
Isotype control
AT1413
Isotype control
AT1413
Isotype control
BM PB SPL TUM0
20
40
60
80
100
% o
f liv
e ce
lls
FACS - human CD38+CD69+ T cells (by SSC - CD45 bright)BM PB SPL TUM
0
20
40
60
T ce
lls/ l
ive
cells
FACS - human T cells (negative selection) % live cells
AT1002 bTCEAT1413 bTCE
AT1413 KiHAT1002 KiH
** *
BLM
MEL06.33
MEL12.07
MEL04.01
MEL06.07
MEL07.16
MEL00.08A
MEL93.15.2
MEL518A2
MEL93.03
MEL03.10
MEL06.04
MEL93.04C
MEL96.11
MEL90.07
MEL94.03
MEL99.08
MEL05.18
MEL05.06
MEL93.08
MEL04.07
MEL93.050
50
100
150
patient-derived melanoma
delta
MFI
positive
MEL12.07
MEL06.07
MEL99.08
Isotype controlAT1413
Melanoma
Leukemia
Coloncarcinoma
Pancreascarcinoma
anti-human IgG-AF647
Mammacarcinoma
136.2 A375 BLM WBO
SH-2 THP-1 K-562 Jurkat
Caco-2 COLO 205 HCT 116 SW480
Capan-2 PANC-1 PANC 08.13 PDX derived
BT-20BT-549 T-47DZR-75-1
1 AIMM Therapeutics, Amsterdam, The Netherlands, 2 Department of Hematology, Academic University Medical Centers, location AMC, Amsterdam, The Netherlands3 Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands, 4 Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands5 Leiden University Medical Center, Leiden, The Netherlands*These authors contributed equally to this work.
G. de Jong*1,2,3,4, L. Bartels*1,4, M. Kedde1, E. Verdegaal5, M.A. Gillissen1,2,3,4, S.E. Levie1, M.G. Cercel1, S.E. van Hal-van Veen1, C. Fatmawati1, D. van de Berg1, E. Yasuda1, Y. Claassen1, A.Q. Bakker1, S.H. van der Burg5, R. Schotte, J. Villaudy1, K. Wagner1, H. Spits1,4, M.D. Hazenberg2,3,4, P.M. van Helden1.
Background
‣ Antibody AT1413 was isolated from a high-risk AML patient who successfully cleared the leukemia after allogeneic stem cell transplantation ‣ AT1413 targets CD43s, a unique sialylated form of CD43 expressed by all of >70 primary AML and MDS isolates tested‣ AT1413 constructed into a bispecific T-cell engaging format (AT1413 bTCE) was effective against primary AML in vitro and in vivo‣ Here we show that CD43s is also present and can be targeted on non-hematopoietic tumors
1. CD43s expression is not restricted to hematologic malignancies
(A) AT1413 binds to melanoma cell lines and a subset of mama carcinoma cell lines as determined by flow cytometry
(B) AT1413 binds 18/21 short-term cultured patient-derived melanoma samples as determined by flow cytometry
(C) Immunohistochemistry staining by AT1413 on a tissue micro array containing 39 patient melanoma samples was positive in 72% of cases.
2. Confirmation of sialylated CD43 (CD43s) as the target of AT1413 on melanoma cells
3. AT1413 T-cell engagers induce T cell-mediated lysis of melanoma cells in vitro
(A) Schematic view of T-cell engager (TCE) formats of AT1413(B) The AT1413-bTCE directed T-cell mediated lysis against two
melanoma cell lines, 136.2 and A375(C) AT1413-KiH induced lysis with lower potency (EC50: 27 nM)
compared to AT1413-bTCE (EC50: 500 pM) on A375
Conclusion‣ AT1413 recognizes a sialylated epitope on CD43 (CD43s) shared by melanoma, AML and MDS‣ Two bispecific AT1413 T-cell engagers targeting CD43s x CD3 redirected T-cell cytotoxicity against melanoma
cells with different potencies in vitro‣ AT1413 TCEs induced strong anti-tumor cytotoxic activities in vivo and T-cell infiltration into the tumor‣ These data indicate a broad therapeutic potential of AT1413.
4. AT1413 T-cell engagers inhibit melanoma tumor growth and increase tumor infiltration in vivo
T-cell engager bispecific formats of an AML patient-derived antibody targeting a unique sialylated CD43 epitope induce kill of melanoma cells in vitro and in vivo
A B
A B
Conflict of interest disclosure:
MK, SL, MC, SvH, CF, DvB, EY, YC, AB, RS, JV and PvH are employees of AIMM Therapeutics.
MK, SL, MC, SvH, CF, DvB, EY, YC, AB, RS, JV and PvH have equity ownership in AIMM Therapeutics.
MK, MG, AB, HS, MH and PvH are inventors on a patent relevant to this subject.
Abstract #4745 Poster #542
A B
(A) Detection of CD43 on Western blot afterimmunoprecipitation of lysed A375melanoma cells using AT1413. M = marker, X= empty lane
(B) Neuraminidase treatment of melanoma andAML cells, which removes sialyl groups fromglycosylated proteins, resulted in loss ofAT1413 binding as detected by flowcytometry. This confirms the AT1413 epitopeis sialylated.
C
(A) Human Immune System mice were engrafted subcutaneously with luciferase-expressing A375 melanoma cells andwere treated as indicated. Normalized tumor growth is depicted over time; AT1413 TCEs inhibited tumor growth by73-77% compared to negative control TCEs.
(B) AT1413-bTCE treatment induced T-cell infiltration into the tumor (C) and a larger lymphocyte infiltrate with anactivated phenotype (CD38+CD69+) compared to mice treated with bTCE control.
C
A B
C Evaluated by two-way ANOVA/mixed-effect analysis, corrected for multiple testing. Error bars represent mean with standard deviation of the mice per treatment group. *: P < 0.05, **: P < 0.01
I. stage III tumor on the upper arm II. stage II tumor on the sole of the footIII. stage III tumor of the scalpIV. Adjacent healthy skin.
Detection by mouse anti-CD43 (clone MEM59)
bTCE (2+2)Bispecific T-cell
engaging antibody
KiH (1+1)Knob-in-hole monovalent T-cell engaging antibody
No FcgR interaction
Knob-into-hole mutations to favor HC heterodimerization
anti-CD3 scFv (UCHT1) to circumvent LC pairing problem
anti-CD3 scFv (UCHT1)
Isotype control bTCE
AT1413 bTCEIsotype control KiH
AT1413 KiH
LegendLegendLegendLegend